Navigation Links
XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
Date:8/15/2008

ce matters, the duties of the audit committee to the extent permitted.

ABOUT XTL BIOPHARMACEUTICALS LTD.

XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of therapeutics for the treatment of diabetic neuropathic pain and HCV. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of diabetic neuropathic pain, which is currently in a Phase 2b study. XTL has out-licensed its novel pre-clinical HCV small molecule inhibitor program. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ and Tel-Aviv Stock Exchanges (Nasdaq: XTLB; TASE: XTL).

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating the continued uninterrupted trading of the Company's ADRs on the NASDAQ Capital Market and the Company's ability to maintain compliance with NASDAQ Capital Market listing requirements, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Risk factors that could adversely affect our operations are identified from time to time in our reports filed with Securities and Exchange Commission, including our annual report on Form 20-F filed with the Securities and Exchange Commission on March 27, 2008. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the dat
'/>"/>

SOURCE XTL Biopharmaceuticals Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
3. XTL Biopharmaceuticals Announces Appointment of Laurence N. Charney to Board of Directors
4. XTL Biopharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
5. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
6. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2008 Financial Results on Monday, May 12, at 8:30 A.M. EDT
7. Keryx Biopharmaceuticals to Present at the Deutsche Bank 33rd Annual Health Care Conference
8. Keryx Biopharmaceuticals Receives Nasdaq Notification
9. Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
10. XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmaceuticals
11. Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... October 22, 2014 Currently offering ... A & D Weighing, Rice Lake, and Ohaus, ... Balance . The Sartorius CPA Semi-Micro Balance is ... high-quality, precise, and user-friendly laboratory balance. , Sartorius ... equipment, their laboratory balances are well known for ...
(Date:10/22/2014)... , Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ... today announced next steps for its Oral Amphotericin ... from its in vitro work involving ... iCo now plans to complete pre clinical studies ... initial Phase 1A clinical trial, utilizing approximately $700,000 ...
(Date:10/20/2014)... Mapp Biopharmaceutical,s valiant effort to produce ... fight the Ebola outbreak will make the public ... of pharmaceuticals can be, according to Kalorama Information.  ... some may be taken aback by the three-month ... knowledge are well aware of the complex issues ...
(Date:10/20/2014)... , Oct. 20, 2014  GenVec, Inc. (NASDAQ: ... Horovitz , Ph.D., from its board of directors effective on ... August 2003, and served as its chairman from June 2006 ... the Nominating and Corporate Governance and Audit Committees of the ... than a decade of dedicated service to GenVec, and its ...
Breaking Biology Technology:Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Zola P. Horovitz To Retire From GenVec Board 2
... Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ... ) today announced that a supplemental New Drug Application (sNDA) ... (FDA) for the expanded use of BYETTA® (exenatide) injection as ... and/or a thiazolidinedione (TZD) in conjunction with diet and exercise ...
... Santiago de Compostela (USC) have analysed levels of radon, a ... results show that 34% of these schools exceed the limit ... of radon is associated with lung cancer. "Out of ... radon levels in excess of 400 Bequerels/m3 in some of ...
... Screening Services (ESS), announced today that they have ... Professional Background Screeners (NAPBS®) accreditation program and will ... (BSCC) Accredited. "We are so pleased ... that we can instill confidence in our existing ...
Cached Biology Technology:Amylin and Lilly Seek Expanded Use of BYETTA® Along with Basal Insulin 2Amylin and Lilly Seek Expanded Use of BYETTA® Along with Basal Insulin 3Amylin and Lilly Seek Expanded Use of BYETTA® Along with Basal Insulin 4Amylin and Lilly Seek Expanded Use of BYETTA® Along with Basal Insulin 5Amylin and Lilly Seek Expanded Use of BYETTA® Along with Basal Insulin 6Amylin and Lilly Seek Expanded Use of BYETTA® Along with Basal Insulin 734 percent of Galician secondary schools exceed maximum recommended radon levels 2ESS Achieves Accreditation From Background Screening Credentialing Council 2
(Date:10/19/2014)... household electricity access in India over the last ... total carbon emissions growth during that time, according ... Nature Climate Change ., "Energy access is ... aspects of life, including education, communication, and health," ... study. , While increased energy access is widely ...
(Date:10/17/2014)... Ebola is critical and pertinent for practicing physicians and ... and epidemic. The Journal, Disaster Medicine and Public ... Virus and Public Health, to surround the public, medical ... societal moment. , On October 17, the journal ... The primer was prepared by Dr. Eric Toner, internist ...
(Date:10/16/2014)... body. Battles are won, lost or sometimes end ... as tumor dormancy—can last up to 25 years ... poorly understood. , A new computational model ... Professor of Chemistry at Princeton University, may help ... switch to a malignant state. Published today in ...
Breaking Biology News(10 mins):Improved electricity access has little impact on climate change 2Modeling tumor dormancy 2
... Researchers from Cleveland Clinic,s Wellness Institute and Harvard University ... sodas is associated with a higher risk of stroke. ... with a lower risk. The study recently ... is the first to examine soda,s effect ...
... surrounding the outside of arteries in humansparticularly the left ... or atherosclerosis, which is the leading cause of death ... the American Heart Association,s Arteriosclerosis, Thrombosis and Vascular Biology ... may help in identifying the molecular culprit, with the ...
... Scientists have identified a link between different strains of ... develop vaccines or drugs against life-threatening cases of the ... is common to many potentially fatal forms of the ... were effective against these severe malaria strains. The ...
Cached Biology News:Study finds soda consumption increases overall stroke risk 2Fat outside of arteries may influence onset of coronary artery disease 2Scientists find Achilles' heel in life-threatening malaria parasites 2
...
... TNT Coupled Reticulocyte Lysate Systems(a,b,c,d) offer ... vitro translations: a single-tube, coupled transcription/translation ... simplify the process and reduce the ... translation results. Standard rabbit reticulocyte lysate ...
... is a fully automated microplate luminescence ... widest possible range of applications based ... assays luciferase, -galactosidase, gene activities with ... Luminescent Immunoassays Cell-based assays ...
... These handy dispensers save space and ... and other garb. They are the ... parts used in labs, processing and ... charges and the particles they attract. ...
Biology Products: